Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | C1S | P09871 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071829 | 0.95 | MAPT (0.35) | SMN1; SMN2MAPTLMNATP53 | |
| Trifluoroacetic Acid SCHEMBL2672126 | 0.92 | C1S (0.32) | C1S | |
| Trifluoroacetic Acid SCHEMBL9902969 | 0.89 | MAPT (0.31) | SMN1; SMN2MAPTSLC2A1 | |
| SCHEMBL4072249 | 0.86 | MAPT (0.34) | SMN1; SMN2MAPTLMNATP53 | |
| SCHEMBL590375 | 0.86 | MAPT (0.37) | SMN1; SMN2MAPTLMNATP53 | |
| Trifluoroacetic Acid SCHEMBL2672359 | 0.80 | — | — | |
| SCHEMBL4063471 | 0.79 | CNR1 (0.39) | SMN1; SMN2MAPTLMNA | |
| Trifluoroacetic Acid SCHEMBL589362 | 0.78 | FFAR1 (0.34) | SMN1; SMN2C1S | |
| Trifluoroacetic Acid SCHEMBL589653 | 0.78 | FFAR1 (0.34) | SMN1; SMN2C1S | |
| Trifluoroacetic Acid SCHEMBL589361 | 0.78 | FFAR1 (0.34) | SMN1; SMN2C1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822474-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20140005154-A1 | 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-02 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005154-A1 | 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases | DPYD, TYMS, TPMT | SMN1; SMN2 797/4885MAPT 2510/4885SLC2A1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.